viewDestiny Pharma PLC

Destiny Pharma lands Brazilian patent for post-surgical nasal gel; expects to share phase IIb results at the end of next month

The Brazilian authorities have issued what is known as a notice of allowance pending full approval next month

Destiny Pharma PLC -

Destiny Pharma PLC (LON:DEST) said Brazil's Industrial Property Office has granted it an additional patent over XF-73, a nasal gel being developed to prevent post-surgical infections such as MRSA.

The Brazilian authorities have issued what is known as a notice of allowance pending full approval next month.

It will be the 84th patent from three patent families covering the XF platform.

In the same announcement, Destiny said it expects to share the results of its ongoing phase IIb trial towards the end of March, after which it will concentrate its efforts on a phase III programme.

“There is also a significant commercial opportunity for XF-73 in the hospital setting which we estimate could generate peak annual product sales of US$1 billion in the US alone,” said the company’s chief executive, Neil Clark in the statement.

Destiny’s product has been awarded both qualifying infectious disease product (QIDP) and Fast Track status by the US Food & Drug Administration (FDA).

Quick facts: Destiny Pharma PLC

Price: 105 GBX

Market: AIM
Market Cap: £62.81 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Destiny Pharma PLC named herein, including the promotion by the Company of Destiny Pharma PLC in any Content on the Site, the Company receives...



Destiny Pharma presents at the Proactive One2One live investment forum

  Destiny Pharma's (LON:DES) Neil Clark (CEO) pitches to investors at the Proactive One2One live virtual forum. Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its...

on 22/1/21

2 min read